TABLE I.

Discovery Cohort Gene Expression and Validation

	mRNA expression					Internal bootstrap analysis N=number of bootstrap samples validation
	No recurrence		Cancer recurrence			Univariate	Multivariable
Gene	Median	Range	Median	Range	P-value	N	N
ALDH1A1	0.01	0.001–45.908	0.416	0.001–58.435	0.82	6	11
AXIN2	2.476	0.001–8.812	1.558	0.001–25.316	<0.001	95	71
Bmil	2.541	0.001–13.726	2.802	0.001–17.036	0.34	14	24
CD133	0.001	0.001–6.568	0.001	0.001–3.031	0.53	10	1
CD44	1.848	0.001–10.102	1.381	0.001–30.536	0.036	53	19
CTNNB1	0.705	0.001–2.957	0.596	0.001–2.611	0.28	18	8
ITGA2	0.001	0.001–1.789	0.001	0.001–2.169	0.31	19	0
NANOG	5.965	0.001–31.189	3.766	0.001–81.742	0.22	23	24
Nkx3 1	24.642	0.001–109.928	27.315	3.223–184.399	0.36	23	25
Notch1	0.001	0.001–0.641	0.001	0.001–0.572	0.3	18	8
POU5F1	0.001	0.001–8.145	1.005	0.001–14.404	0.017	64	48
TACSTD2	86.601	19.276–251.149	65.594	8.006–293.531	0.008	70	47

For each of the 12 genes tested, median normalized gene expression scores and range are shown for patients with versus without disease recurrence. Genes that were differentially expressed with statistical significance between patients with recurrence versus without are in BOLD (AXIN2, CD44, POU5F1, TACSTD2). Of these, all four remained significant (N > 50) in the univariate bootstrap analysis, and AXIN2 also remained significant in the multivariable analysis.